Hydroxychloroquine a valuable therapeutic to fight Covid. All the evidence you need

I see poor ou sharkie has attempted in some vague way to discredit Hydroxychloroquine. Mozzzietard tries to make a contribution but flops badly. Blobbie just gives a grunt or two! Worse performanc than even his legendary klop!

There are two camps on this issue. The Globalist camp represented by WHO, Lancet and Globalist Media like the far left rag, the Washington post want you to believe Hydroxy is ineffective and even dangerous.

Of course Hydroxy can be dangerous if taken incorrectly!! Most drugs are. However as a treatment for malaria etc it has been used safely by billions.

I am not sure why anybody today would think the Globalist media and health entities can be relied on. They have been wrong on about everything. What have they been right on?

Trump was right to recommend Hydroxy. Trump was dupoed by the team Judas Pence assembled and thought the vaccines would help. He also was led to believe by these so called experts that Remdesivir and ventilators would help. But he was not duped into forcing anybody to take the deadly jab and wanted the economy opened as fast as possible.

So lets look at some evidence. 

Early treatment with hydroxychloroquine cut the death rate significantly in certain sick patients hospitalized with COVID-19 — and without heart-related side-effects, according to a new study published by Henry Ford Health System. 

The study, published Thursday in the International Journal of Infectious Diseases, is another curve in the continued research — and its sometimes conflicting results — into whether a drug that seemed promising at the beginning of the COVID-19 pandemic really works.

The Henry Ford study examined outcomes of 2,541 patients hospitalized with COVID-19 between March 10 and May 2 across the Michigan system’s six hospitals. Overall, 18 percent of the patients died in the hospital.

But there were marked differences in their treatment.

Among those who received hydroxychloroquine as part of early treatment, 13 percent died, compared to 26 percent of those who did not receive the drug. 

Mortality among all patients was highest among those who were older than 65, white, and were admitted with already-reduced oxygen levels. They also commonly had serious underlying diseases, including chronic kidney and lung disease.

Dr. Marcus Zervos, head of infectious disease at Henry Ford Health System, acknowledged that Henry Ford’s results differ from other studies.

“There’s variability in the literature on outcomes with hydroxychloroquine... What we think was important in our study was our patients were treated early. And for hydroxychloroquine to have a benefit, it needs to be given before the patient suffers some of the severe immune reaction that can occur with COVID.”

That’s because the drug works by inhibiting the immune system’s inflammatory response to the virus, Zervos said. 

Patients were monitored for possible heart issues, he added, and anyone who was at risk for cardiac abnormalities was excluded from the study.  

While it is critical to use hydroxychloroquine in combination with other treatments, such as steroids, Zervos said these findings suggest the drug could be helpful in treating COVID, especially in other countries that don’t have access to the antiviral drug, Remdesiver, which may reduce illness in some COVID-19 patients.

“Many of these countries, they could be low-income settings. They don’t have access to Remdesivir. Remdesivir is going to be expensive. Hydroxychloroquine is inexpensive. So I think the drug does have a role,” Zerovos said. 

Hydroxychloroquine, sold as a generic or under the brand name Plaquenil,  is used to prevent or treat mosquito-carried malaria, as well as certain auto-immune diseases such as lupus and arthritis.

In the earliest days of the pandemic, doctors reported that some patients appeared to recover more quickly with hydroxychloroquine. The drug’s profile skyrocketed in March after Tesla CEO Elon Musk tweeted a reference, and President Trump lauded its potential as a game-changing medication and urged patients to give it a shot. 

But scientists quickly urged caution as doctors began to report potentially deadly changes to the heart’s rhythm. In April, the U.S. Food and Drug Administration warned against use of the drug outside a closely-monitored hospital setting or clinical trial. Then last month, the FDA withdrew hydroxychloroquine sulfate and the related chloroquine phosphate from the Strategic National Stockpile for use among hospitalized COVID-19 patients.

Confusing matters more, two high-profile studies — including one that suggested hydroxychloroquine was unsafe — were retracted from the respected journals, The New England Journal of Medicine and The Lancet, after researchers questioned irregularities in the data.

A study to determine whether hydroxychloroquine may prevent COVID-19 infection is also underway at Henry Ford. The randomized, double-blinded WHIP study will examine 3,000 first responders and health care workers. There are 619 people currently enrolled.

From Oxford University

Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn’t work in treatment of hospitalised patients, (Needs to be used early) it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding ou t

Design Retrospective monocentric cohort study, with comprehensive data collection authenticated by an external bailiff and death reports from a national database (French National Death Registry).

Setting Institut Hospitalo-Universitaire Méditerranée Infection Center in Marseille, France.

Participants All adults older than 18 years with PCR-proven COVID-19 who were treated directly in our centre between 2 March 2020 and 31 December 2021 and did not refuse the use of their data.

Interventions HCQ and azithromycin (HCQ-AZ) as a reference treatment were compared to other regimens containing HCQ, ivermectin and azithromycin alone, combined, or none of these three drugs. The effect of vaccination was also evaluated.

Main outcome measures 6-week all-cause mortality. Multivariable logistic regression estimated treatment effectiveness with adjustments for age, sex, comorbidities, vaccination, period of infection or virus variant, and outpatient or inpatient care.

Results Total 30,423 COVID-19 patients were analysed (86 refused the analysis of their data) including 30,202 with available treatment data, and 535 died (1.77%). All-cause mortality was very low among patients < 50 years (8/15,925 (0.05%)) and among outpatients treated with HCQ-AZ (21 deaths out of 21,135 (0.1%), never exceeding 0.2% regardless of epidemic period). 

HCQ-AZ treatment was associated with a significantly lower mortality rate than no HCQ-AZ after adjustment for sex, age, period and patient care setting (adjusted OR (aOR) 95% confidence interval (CI) 0.55, 0.45-0.68).

The effect was greater among outpatients (71% death protection rate) than among inpatients (45%). 

In a subset of 16,063 patients with available comorbidities and vaccinations status, obesity (2.01, 1.23-3.29), chronic respiratory disease (2.93, 1.29-6.64), and immunodeficiency (4.01, 1.69-9.50), on the one hand, and vaccination (0.29, 0.12-0.67) and HCQ-AZ treatment (0.47, 0.29-0.76), on the other hand, were independent factors associated with mortality. HCQ, alone or in any association, was associated with significant protection from death among outpatients (0.41, 0.21-0.79) and inpatients (0.59, 0.47-0.73).

Conclusions HCQ prescribed early or late protects in part from COVID-19-related death. During pandemic health crises, financial stakes are enormous. 

April 11 Update: A new research study reveals that COVID-19 attacks hemoglobin in red blood cells, rendering it incapable of transporting oxygen. In the conclusion, researchers found that chloroquine could prevent the virus attacking the hemoglobin in the red blood cells.

Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.  Dr. Zelenko said he saw the symptom of shortness of breath resolved within four to six hours after treatment. Hydroxychloroquine is now being used worldwide, according to a map from French Dr. Didier Raoult.  In the meantime, scientists at University of Pittsburgh School of Medicine believe they’ve found potential vaccine for coronavirus.

Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York. In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.

Dr. Zelenko said the whole treatment costs only $20 over a period of 5 days with 100% success. He defines success as “Not to die.” Dr. Zelenko first posted his Facebook video message last week calling on President Trump to “advise the country that they should be taking this medication.”

There are many other success stories about hydroxychloroquine across the country. Last week, Dr. William Grace, an oncologist at Lenox Hill Hospital in New York City, said they’ve not had a single death in their hospital because of  hydroxychloroquine. “Thanks to hydroxychloroquine, we have not had a death in our hospital,’ Dr. Grace said.

Also, in a study conducted by the National Institute of Health (NIH) also confirmed some of Dr. Dr. Zelenko’s findings. The study by NIH showed that Zinc supplementation decreases the morbidity of lower respiratory tract infection in pediatric patients in the developing world. A second study also conducted by NIH titled: “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),” also showed hydroxychloroquine to be more potent in killing the virus off in vitro (in the test tube and not in the body).

Below is a video of his latest interview explaining the success of the treatment.

Zelenko video

Oaks I could go on and on and on.

We all should know by now why these genocidal maniacs tried to smear Hydoxy and Ivermectin etc.

Trump’s medical advice cost him the election, you could likely see him losing the White House in slow motion at the COVID briefings. I don’t believe he ever advised Americans to use bleach, but his statements were sufficiently vague that an antagonistic media could pin it on him.

As far as HCQ is concerned there are conflicting studies and it’s hard to know what to believe. 

This from Forbes is good advice, not that the Donald takes much advice:

‘ This takes nothing away from the positive work of the Trump Administration during the Covid-19 pandemic, igncluding its efforts initiating Operation Warp Speed, a public-private partnership to facilitate and accelerate the development, manufacturing, and distribution of Covid-19 vaccines, therapeutics, and diagnostics. This program has been hugely successful, as measured by the pace at which Covid-19 vaccines and treatments were developed and launched.

But Trump’s issuance of unwarranted treatment recommendations left a lot to be desired. All such governmental advice must be tightly regulated and given only by those with the requisite knowledge and expertise.